Show simple item record

dc.contributor.authorSingh, Mohit
dc.contributor.authorKeer, Dipinder
dc.contributor.authorKlimas, Jan
dc.contributor.authorWood, Evan
dc.contributor.authorWerb, Dan
dc.date.accessioned2016-02-18T10:01:05Zen
dc.date.available2016-02-18T10:01:05Zen
dc.date.issued2016-01-30en
dc.identifier.citationTopiramate for Cocaine Dependence: A Systematic Review and Meta-Analysis of Randomized Control Trials. 2016: Addictionen
dc.identifier.issn1360-0443en
dc.identifier.pmid26826006en
dc.identifier.doi10.1111/add.13328en
dc.identifier.urihttp://hdl.handle.net/10147/596595en
dc.description.abstractTo assess the efficacy of topiramate in treating cocaine use disorder (i.e., retention, efficacy, safety, and craving reduction) through a systematic review and meta-analysis.
dc.description.abstractWe searched six scientific databases from inception to December 23, 2014 with no date limits. Data were systematically reviewed, extracted and analyzed. Studies were included if they were peer-reviewed randomized control trials with participants meeting diagnostic criteria for cocaine dependence or cocaine use disorder, with the treatment arm involving topiramate with or without psychosocial intervention, and the control arm involving no intervention or psychosocial intervention with or without placebo. A random-effects meta-analytic model was computed.
dc.description.abstractFive studies met inclusion criteria (n = 518). Topiramate was compared with placebo (4 studies), and no medication (1 study). In a meta-analysis, we observed no significant differences between topiramate and placebo in improving treatment retention (risk ratio [RR] = 0.84; 95% Confidence Interval [CI]: 0.67-1.05, p = 0.12). However, compared with a placebo, use of topiramate was associated with increased continuous abstinence in two of five studies (RR = 2.52; 95% CI: 1.35-4.73, p = 0.004). No differences were observed in frequency of adverse effects reported between topiramate and placebo (RR=1.03; 95% CI = 0.87-1.23, p=0.72). Topiramate was significantly associated (p<0.05) with a reduction in craving in only one of five studies.
dc.description.abstractEvidence does not currently support the use of topiramate to improve treatment retention for cocaine use disorder, though it may extend cocaine abstinence with a similar risk of adverse events compared with placebo.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Addiction (Abingdon, England)en
dc.subjectCOCAINE-RELATED DISORDERSen
dc.subjectSUBSTANCE MISUSEen
dc.subjectADDICTIONen
dc.titleTopiramate for Cocaine Dependence: A Systematic Review and Meta-Analysis of Randomized Control Trials.en
dc.typeArticle In Pressen
dc.identifier.journalAddiction (Abingdon, England)en
refterms.dateFOA2016-02-17T00:00:00Z
html.description.abstractTo assess the efficacy of topiramate in treating cocaine use disorder (i.e., retention, efficacy, safety, and craving reduction) through a systematic review and meta-analysis.
html.description.abstractWe searched six scientific databases from inception to December 23, 2014 with no date limits. Data were systematically reviewed, extracted and analyzed. Studies were included if they were peer-reviewed randomized control trials with participants meeting diagnostic criteria for cocaine dependence or cocaine use disorder, with the treatment arm involving topiramate with or without psychosocial intervention, and the control arm involving no intervention or psychosocial intervention with or without placebo. A random-effects meta-analytic model was computed.
html.description.abstractFive studies met inclusion criteria (n = 518). Topiramate was compared with placebo (4 studies), and no medication (1 study). In a meta-analysis, we observed no significant differences between topiramate and placebo in improving treatment retention (risk ratio [RR] = 0.84; 95% Confidence Interval [CI]: 0.67-1.05, p = 0.12). However, compared with a placebo, use of topiramate was associated with increased continuous abstinence in two of five studies (RR = 2.52; 95% CI: 1.35-4.73, p = 0.004). No differences were observed in frequency of adverse effects reported between topiramate and placebo (RR=1.03; 95% CI = 0.87-1.23, p=0.72). Topiramate was significantly associated (p<0.05) with a reduction in craving in only one of five studies.
html.description.abstractEvidence does not currently support the use of topiramate to improve treatment retention for cocaine use disorder, though it may extend cocaine abstinence with a similar risk of adverse events compared with placebo.


Files in this item

Thumbnail
Name:
Singh_et_al-2016-British_Journ ...
Size:
494.1Kb
Format:
PDF
Description:
main manuscript

This item appears in the following Collection(s)

Show simple item record